FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to a federal compounding list.
A government health group said yes to letting Hims & Hers make four new kinds of medicine (called peptides). This shows the company might be allowed to offer new treatments, which people will watch to see if it helps the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.